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                                     Abstract                                                                                                     
Influenza A virus is an important respiratory pathogen with the potential to affect both humans 
and animals, thereby creating the conditions for public health disasters, especially during 
pandemic episodes. At present, two primary strategies to combat influenza are vaccination and 
antiviral drugs. Since influenza viruses mutate rapidly and constantly via antigenic drift and 
shift, vaccines can become quickly outdated; and resistance to antiviral drugs can readily result. 
Interferon alpha (IFN-α) plays an important role as a first line of innate antiviral immunity. To 
investigate the antiviral potential of exogenously applied IFN-α on the replication of different 
subtypes of influenza A viruses, three subtypes of influenza A virus, i.e. swine H3N2, pandemic 
H1N1 and avian H9N2 were chosen. Their replication kinetics in the presence of Alferon N 
(human Interferon alpha) on human epithelium (A549) cells and swine testis (ST) cells was 
evaluated. In these tests of the three subtypes of influenza A viruses, it was found that the 
replication ability of all three viruses was inhibited when ST cells were treated with Alferon for 
four hours before infection. The ability of Alferon to inhibit influenza A viruses replication was 
found to be dose-dependent. Similar results were obtained when A549 cells were used; however, 
pretreatment of A549 cells with Alferon for more than 16 hours was necessary before infection. 
Furthermore, the expression of some ISGs (Interferon stimulated genes) between ST and A549 
cells was also investigated. The differences in response of the ISGs between the two cell lines 
provided an explanation of the disparity towards exogenous interferon treatment. In summary, 
these results demonstrated that Alferon N has the ability to inhibit replication of different 
subtypes of influenza A viruses in cell cultures. This study provides a foundation for future in 
vivo studies using exogenous IFN-α treatment as an alternative approach to combat influenza A 
virus infection. 
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Chapter 1 - Influenza Virus Literature Review 
 1.1 Introduction 
Influenza is an infectious disease caused by RNA viruses of the family orthomyxoviridae. 
The symptoms in humans include fever, coughing, sneezing, sore throat, muscle pain and 
fatigue. This disease affects various species such as humans, pigs, birds, ferrets, dogs, etc. It 
circulates constantly among susceptible species as seasonal epidemics causing significant 
economic loss and health burdens. Around 30,000 to 50,000 influenza-related deaths have been 
estimated to occur each year in the United States. It also causes a pandemic every 10 to 50 years, 
with a significant number of human deaths (72). Three main influenza pandemics occurred in the 
20
th
 century—1918 Spanish flu, 1957 Asian flu, 1968 Hong Kong flu—and one in the 21st 
century, the 2009 swine flu. There were over 20 million human deaths because of the 1918 
Spanish flu alone.  Clearly, influenza still poses a significant public health threat.  
 1.2 Orthomyxoviridae Family  
The Orthomyxoviridae family is a family of RNA viruses that consist of five genera: 
Influenza A, Influenza B, Influenza C, Isavirus and Thogotovirus.  Influenza is caused by 
influenza A, influenza B and influenza C genera among birds and mammals. Each genus has one 
type of species which is influenza A virus, influenza B virus and influenza C virus respectively. 
Influenza A draws the most attention among them because of its ability to cause influenza 
pandemics. Influenza B viruses can cause the same spectrum of diseases as influenza A viruses 
and can cause substantial morbidity. Therefore, the trivalent seasonal influenza vaccine contains 
an influenza B virus component. However, influenza B viruses do not cause pandemics, mainly 
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because they infect only humans and occasionally seals (57); and reassortment between new 
strains is less likely to happen. Influenza C viruses are isolated from and infect humans and pigs 
(24), causing mild upper respiratory illness rather than severe lower respiratory tract 
complications. There is currently no vaccine for influenza C virus.  
 1.3 Influenza A Virus 
 1.3.1 Virus Structure and Genome 
The influenza A virus genome consists of 8 negative sense, single strand RNA segments; 
and each segment encodes one or two proteins. Thus up to 11 or 12 proteins are encoded by the 8 
viral genes (49): segment 8 encodes the host antiviral response antagonist non-structural protein 
(NS1) and  the nuclear export protein (NEP, also named NS2); segment 7 encodes the matrix 
protein M1 and the ion channel M2; segment 4 encodes the receptor-binding protein 
heamagglutinin (HA); segment 6 encodes the sialic acid destroying enzyme neuraminidase (NA); 
segment 5 encodes nucleoprotein (NP); and segments 1, 2 and 3 encode components of 
polymerase complex polymerase basic (PB)2, polymerase basic (PB)1 and polymerase acid (PA) 
respectively.  Besides PB1, segment 2 has been reported to encode N40 whose function is still 
unknown (80). Moreover, PB1 in some viruses encodes a pro-apoptotic virulence factor named 
PB1-F2 by using an alternative open reading frame (ORF) in the PB1 segment (12).  
Influenza A viruses are pleomorphic viruses with a lipid envelope derived from the 
plasma membrane of infected cells. These viruses are either spherical with a diameter around 
100nm or filamentous with a length of more than 300nm by electron microscopy. There are three 
proteins located in the envelope: HA, NA, M2 proteins.  HA and NA proteins, which are 
glycoproteins, form spikes which protrude from the surface of the influenza virion in a ratio of 
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approximately four to one. HA proteins are present as rod-shaped spikes while NA proteins are 
present as mushroom-shaped spikes, with both proteins anchored in the viral envelope by a  short 
sequence of hydrophobic amino acids (13, 55). HA, and to a lesser extent NA, are highly 
variable and represent major targets for the host humoral immune response.  The small amount 
of M2 protein integrated in the envelope serves as an ion channel, playing an important role in 
the virus uncoating process. Beneath the envelope is the matrix protein (M1) which encloses the 
virion core and supports the morphology of influenza particles.  Inside the matrix proteins are 
nuclear export proteins (NEPs) (also called NS2s) and the ribonucleoproteins (RNPs) complex 
which represent the virion core. The RNP complex consists of a viral genome RNA in 
association with nucleoproteins (NP) and the RNA-dependent RNA polymerase complex, 
represented by PA, PB1 and PB2 proteins.  The RNPs are the fundamental units which are 
responsible for viral replication and transcription (55).  
Based on the two glycoproteins on the surface of the virus, namely hemagglutinin (HA) 
and neuraminidase (NA), Influenza A viruses are divided into different subtypes. Before 2012, 
16 different HA and 9 different NA subtypes had been described in various combinations; and a 
novel HA subtype (H17) has recently been isolated from fruit bats (73). Theoretically, different 
combinations between HA and NA can occur resulting in a multitude of different subtypes. 
Reverse genetics enables the generation of all of these subtypes under laboratory conditions. 
However, the viability of the generated viruses or their virulence remains unknown.  
Different subtypes might have different host tropisms; however, H17 has been found in 
fruit bats which might constitute a potential mammalian host for influenza A viruses (73). All 16 
HA and 9 NA have been found among wild waterfowl and seabirds, which are believed to be the 
natural reservoir for influenza A viruses (IAVs) (56). Some subtypes preferentially circulate in 
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certain species. For example, H1, H3, N1 and N2 are predominantly isolated from humans and 
pigs worldwide, while H3N8 and H7N7 circulate preferentially in horses. The host barrier for 
influenza A viruses is restricted under normal conditions; however, the barrier can be broken due 
to antigenic drift or antigenic shift. Antigenic drift is the random mutation that happens 
constantly within individual genes due to the lack of proofreading. Antigenic shift occurs when a 
virus acquires new HA, and possibly NA segments from a different subtype, resulting in a novel 
virus strain. Antigenic shift can occur when a host is infected by two or more different subtypes 
of influenza A viruses. Since the resulting new virus strains encode antigenic proteins (HA and 
to a less extent NA) to which the host has no pre-existing immunity, pandemic influenza can 
occur.  
 1.3.2 Replication 
 1.3.2.1 Virus Attachement  
Virus attachment to the target cells is the first step for infection. Influenza A viruses 
recognize N-acetylneuraminic (sialic) acid which is ubiquitously expressed on many host cell 
types and in many species. The surface sialic acid terminal binds through its carbon-2. Based on 
whether the carbon-2 binds to carbon-3 or carbon-6 galactose, there are two type of surface sialic 
acid: α-2, 3-linkake and α-2, 6-linkage (54). Different virus strains have different preference to 
bind either α-2, 3-linkage or α-2, 6-linkage via the HA. Normally, human and swine influenza 
viruses preferentially bind to α-2, 6-linkage, while avian and equine influenza viruses 
preferentially bind to α-2, 3-linkage (74). Therefore, the distribution of different types of sialic 
acids will determine the susceptibility to certain types of influenza A viruses (IAVs). In humans, 
the α-2, 6-linkaged sialic acid is predominantly expressed in the upper respiratory tract, whereas 
the α-2, 3-linkage is predominantly expressed in intestinal tissues in poultry (54). To a certain 
5 
 
extent, α-2, 3-linkaged sialic acid can be expressed in the upper respiratory tract in humans 
which explains why this species can become infected by avian influenza viruses, even though 
with less efficiency than by human influenza strains. In addition, the concentration of α-2, 3-
linkaged sialic acid receptors is higher in the lower respiratory tract (bronchioles and alveoli) 
which might explain the high pathogenicity of some avian influenza strains for humans. 
Replication of highly pathogenic avian influenza H5N1 viruses in the lower respiratory tract of 
humans is most likely the reason for its high virulence.  Humans are less susceptible to avian 
influenza; however, more severe clinical symptoms will result once they become infected. 
 1.3.2.2 Virus Entry  
After attachment and being recognized by the host receptors, influenza viruses enter host 
cells by receptor mediated endocytosis. During entry, the viruses are encapsulated inside of the 
endosome and translocated to the places near the nucleus. The acidification in the mature 
endosome (PH around 5) facilitates the uncoating process of viruses and helps release vRNPs 
into the cytoplasm (42). This process has two significant steps. First, low pH triggers a 
conformational change in the HA, exposing a fusion peptide that mediates the fusion of viral 
envelope with the host membrane, thus opening a pore through which the viral RNPs are 
released into the cytoplasm. Second, before the membrane fusion happens, the hydrogen ions 
from the endosome enter the viral particle via the M2 ion channel, creating an acid environment 
which disrupts M1 Matrix proteins polymerization and interaction between M1 and RNPs, 
allowing uncoating, i.e., the release of the RNPs from the viral matrix into the cellular cytoplasm 
(8). 
 1.3.2.3 Synthesis of Viral RNA 
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Unlike most other single stranded RNA viruses, the replication and transcription of IAVs 
take place in the nucleus (8). After release from the virion, RNPs and the viral proteins are 
imported into the nucleus directed by nuclear localization signals (NLSs) (8). The viral RNA-
dependent RNA polymerase uses the negative sense vRNA as a template to synthesize positive 
sense mRNAs and cRNAs. mRNA serves as a template for viral protein synthesis, while cRNA 
is transcribed to produce more copies of negative sense, genomic vRNA immediately. The 
regulation process between the replication and transcription is still not well-known. Influenza 
viruses have unique ways to add 5’cap and 3’ poly (A) tail to the mRNA. Generally, the virus 
can snatch the host mRNA 5’ methylguanosine cap with 10-15 nucleotides downstream by the 
endonuclease activity of its PB2 and use it as template to transcript viral mRNA (13). For the 3’ 
poly (A) tail, the vRNA encodes five to seven uracil residues approximately 17 bases from its 5’ 
end. This is where the transcription stops and the viral polymerase transcribes the poly U tract 
into the positive sense as a string of adenosines that form the poly (A) tail. So the mRNA is an 
incomplete copy with around 17 bases less than the complementary vRNA (13). Once 
polyadenylated and capped, the viral mRNA is ready to be translocated to the cytoplasm and 
translated like the host mRNA, while the vRNA segments are exported from the nucleus by the 
NEP and M1 proteins.  
  1.3.2.4 Synthesis of Viral Proteins and Assembling 
The polymerase subunit proteins PA, PB1 and PB2 are translated using viral mRNA as a 
template and then transported into the nucleus by the NLS signals they contain after 
trimerization. A portion of M1 proteins is transported to the nucleus while the remaining stay in 
the cytoplasm. Also, the NEP proteins are imported into the nucleus through free diffusion due to 
their small size (8).  Both M1 and NEP are needed for the RNPs exportation to form new viral 
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particles (9).  Viral protein synthesis is closely related to the amount of corresponding mRNA 
which is transcribed in a selective process. Different quantities of vRNAs are preferentially 
present at different stages of infection (13). The membrane proteins HA, NA, and M2 proteins 
are synthesized during the late stage of infection (13). Using viral mRNA as template, they are 
synthesized on membrane bound ribosomes in the endoplasmic reticulum with further maturation 
in the Golgi apparatus then directed to the cell membranes for subsequent assembly. The 
remaining viral proteins are synthesized in the cytoplasm in preparation for the virion assembly. 
Two different models have been proposed for viral assembly.  One is random packaging model 
which predicts that the viral segments will be randomly packaged into virions, the other is 
specific packaging model which predicts that the viral segments will be selectively packaged into 
virion by signals on each RNA segments (65).  
 1.3.2.5 Virus Budding and Release 
Influenza virus budding occurs at the cell membrane. The progeny virions bind to sialic 
acid on the cell membranes and accumulate in the budding sites. This aggregation may reduce 
viral spreading. This process can be reversed by NA proteins, which function as sialidases by 
cleaving terminal sialic acid residues from cell-surface glycoproteins and gangliosides, releasing 
progeny virus from the host cells. The antiviral drug, Oseltamivir (Tamiflu) is a NA inhibitor 
which blocks the NA activity, preventing the spread of viral particles and inhibiting viral 
replication.                               
     1.3.3 Pathogenicity and Transmission 
Different influenza A virus strains possess different capabilities to infect and transmit 
among host species. The seasonal influenza A virus transmits very well among humans; 
however, the infection in most cases is relatively mild. The highly pathogenic H5N1 virus causes 
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severe pneumonia resulting in systematic infection and multiple organ failure; however, human-
to-human transmission is very limited. Meanwhile, the range of severity of disease caused by 
genetically similar influenza A viruses in humans is extremely wide.  The same virus infection 
will result in different disease severity among individuals. Thus understanding the factors 
determining the pathogenicity and transmission of a virus is pivotal for understanding influenza 
A viruses in order to control and prevent future influenza epidemics and pandemics. Substantial 
amounts of research have been done to investigate these factors, indicating that both virus and 
host factors contribute to the pathogenicity and transmission of IAVs (22, 49) . The 
establishment of reverse genetics for influenza viruses provides a significant tool to elucidate the 
role of each viral protein (22). In addition, animal models (including mice, guinea pigs, ferrets, 
and pigs) are being used in experiments to study virus and host factors related to pathogenesis 
and transmission (49).  
 1.3.3.1 Virus Factors 
HA: In order for influenza A viruses to infect cells, their HA has to bind to certain types 
of sialic acid. As noted previously, human influenza A viruses preferentially bind to α-2, 6- sialic 
acid and avian influenza A viruses bind to α-2, 3-sialic acid.  HA is responsible for targeting 
cells for infection and determining the organ and host tropism.  In humans, the α-2, 6- sialic acid 
is predominantly expressed by the epithelial cells in the upper respiratory tract (67), which 
explains why seasonal IAVs transmit so easily between humans but with less severity. The HA 
of highly pathogenic H5N1 influenza virus binds to α-2, 3 sialic acid which is expressed 
relatively more in the lower respiratory tract of humans; therefore, it can cause severe 
pneumonia. However, the poor transmission ability of H5N1 is partially due to the sparse spread 
of α-2, 3 sialic acid in the upper respiratory tract. Mutations on the HA genes may change the 
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receptor binding preferences, pathogenicity and transmission ability of influenza A viruses. The 
D222G mutations in HA pandemic H1N1 show an increased ability to bind to avian-like (α-2, 3) 
sialic acid and decreased avidity for human-like (α-2, 6) sialic acid (6). These facts remind us to 
pay close attention to the HA mutations in H5N1 as well as seasonal H1N1 for their pandemic 
potential.  
HA influences pathogenicity in another way by its susceptibility to host proteases. The 
requirement for a virus infection to occur is that its HA proteins become cleaved to HA1 and 
HA2 to expose the fusion protein. The HA of seasonal IAV and most low pathogenic influenza 
viruses possesses a single arginine at the cleavage site that can be cleaved by extracelluler 
trypsin-like protease that is present at respiratory surfaces or in the intestines of the host (22, 49); 
however, the HAs of highly pathogenic H5N1 process multiple basic amino acids within the 
cleavage site can be cleaved by furin and PC6 which are ubiquitously expressed in many organs 
(13). This might explain why the HPAIV can cause severe systematic infection (29). HA with 
multiple basic amino acids near a cleavage site can be viewed as one sign of high pathogenicity 
(13). 
The RNP complex: HA is not the only factor to determine influenza virus pathogenicity 
and transmission ability, since the 1918 Spanish flu didn’t have the multibasic amino acids at the 
cleavage site but still had devastating results. It is believed the viral polymerase complex (PA, 
PB2, PB1), the fundamental requirement for virus replication and transcription, is also 
responsible for determining virus pathogenicity. By replacing the genes except for the 
polymerase complex and NP from the 1918 influenza virus with those from the a seasonal 
influenza strain, the virulence property showed similarity with the wild type 1918 in both the 
upper and lower respiratory tracts of ferrets, indicating that  the polymerase complex is the major 
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determinant of the pathogenicity of the 1918 pandemic virus (79). Substituting lethal H5N1 
polymerase genes with genes from nonlethal H5N1 reduced the virus virulence and polymerase 
activity (64). Several mutations in the PA and PB2 genes also changed the virus tropism, 
adapting the avian strains to infect mammals (10, 41, 69). In addition, the post-translational 
modification of the polymerase gene complex and NP genes will also alter the virus infectivity 
(59). 
PB1-F2: This 11
th
 protein of influenza A viruses, discovered approximately 10 years ago, 
is a 90-amino acid protein preferentially located in the mitochondria of infected cells (12). 
Researchers have shown that the pleiotropic function of PB1-F2 contributes to an enhanced 
pathogenicity. The PB1-F2 protein induces immune cell apoptosis in response to influenza virus 
infection. The PB1-F2 protein also works as a virulence factor and increases mortality and 
pathogenicity and promotes secondary bacterial infection (47, 83). The S66 residue in PB1-F2 is 
found in both 1918 pandemic virus and HAPI H5N1 and substitution of this residue will result in 
reduced virulence for both viruses (15).  Also, by directly interacting with PB1, PB1-F2 
regulates polymerase activity  through phosphorylation, resulting in an increased virus 
replication (46). In some viruses, it has been found that PB1-F2 can work together with NS1 
protein to inhibit the host IFN system (77).  New data suggest that some functions of PB1-F2 are 
strain and host specific (36). More research needs to be done to elucidate how PB1-F2 
contributes to pathogencity (36).  
NS1: The influenza A virus NS1 gene encodes a protein about 26.8 kD, which works as a 
homodimer during virus infection. NS1 has been shown to be an alpha/beta interferon antagonist 
both in vitro and in animal systems (68). It enhances viral pathogenicity by counteracting the 
innate immune system. The N terminus of NS1 binds to and sequesters dsRNA, and thereby 
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blocks the activation of RIG-1, 2’-5’ OAS, PKR, or other dsRNA-activated proteins during virus 
infection. The C terminus of NS1 can block the activity of the nuclear proteins PABPII and 
CPSF, preventing the processing and export of mRNA transcripts. The whole NS1 gene is 
required to ensure optimal interferon antagonist function in vitro and in vivo. The ability to 
counter IFN-alpha/beta in vitro was shown to be decreased in NS1 Carboxy-truncated Tx/98 
virus compared to wild Tx/98 with the whole NS1 segment (68).  The severe lung pathology 
caused by 1918 influenza was likely due in part to its NS1 gene. The 1918 NS1 protein induced 
numerous pro-inflammatory chemokine and cytokine genes. The product of many of these genes 
served to attract and activate infiltration of immune cells with inflammatory functions. Also, the 
1918 NS1 down-regulated the expression of IFN-stimulated genes which are the first line of host 
response against virus infection (7).  
 1.3.3.2 Host Factors 
Host receptors: Influenza A virus replication starts by interaction between virus HA 
proteins and the host cell receptors. Sialic acid has been identified as a receptor determinant for 
influenza A viruses. The distribution of this receptor varies between host species and different 
organs in the same host species, resulting in the different pathogenicity and transmission 
characteristics of influenza viruses. The use of sialic acid linkage-specific lectins, like Maackia 
amurensis (MAA, specific for α2-3-linkage) and Sambucus nigra (SNA, specific for α2-6-
linkage), enables the study of sialic acid localization in organs and species. As previously noted, 
in humans, mammalian like (α2-6-linkages) sialic acid is predominantly expressed in the upper 
respiratory tract, which supports the binding of seasonal influenza and supports its easy 
transmission. The avian like (α2-3 linkages) sialic acids are mainly expressed in the human lower 
respiratory tract (alveoli) which supports  infection by avian H5N1 viruses (54).  Pig respiratory 
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tract express a substantial amount of both avian-like and mammalian-like sialic acid in their 
tracheal epithelial cells (54), making them susceptible for both avian and human influenza 
viruses co-infection. Pigs are believed to work as a “mixing vessel”, where virus reassortment 
can happen and result in novel influenza virus strains posing a pandemic threat (49). 
Host immune system: The host immune system determines the outcome of viral 
infection by interacting with the  influenza viruses to form an acute infection, normally lasting 
one to two weeks (16), so the innate and humoral immune responses  play a major role in 
combating influenza virus infections, while T cell mediated immunity is responsible for virus 
clearance (16).  
Innate immunity:  Innate immunity is the first line of defense against invading 
pathogens. It recognizes the pathogen associated molecular patterns (PAMP) and endogenous 
danger signals by pattern recognition receptors (PRR), sending the infected cells and their 
neighboring cells into an altered state by inducing secretion of interferon to upregulate 
interferon-stimulated genes (ISGs) to build an anti-viral status and secretion of chemokines and 
cytokines which attract immune cells (35).  
TLR pathway: TLR3 and TLR7 have been reported to recognize influenza virus RNA 
during virus replication. TLR3 recognizes double stranded RNA while TLR7 recognizes single 
stranded RNA. Activation of TLR3 and TLR7 results in the activation of IRF3 and IRF7, 
respectively, along with AP1, and p50/p65. IRF3 and IRF7 will eventually initiate transcription 
of IFN beta and alpha which have strong antiviral effects by limiting host and viral protein 
synthesis (35). These IFNs can also induce downstream ISGs’ expression and inhibit viral 
replication. On the other hand, AP1 and p50/65 can induce pro-inflammatory cytokines. TLR 
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deficient mice show enhanced mortality along with reduced inflammatory reaction by influenza 
A virus infection (39, 75). 
The RLR (RIG-I like receptors) pathway: When an influenza virus infects a cell, the 5’-
triphosphate single stranded RNA accumulated during virus replication is recognized by retinoic 
acid-inducible gene-I (RIG-I). The activation of RIG-I induces the production of type I IFNs and 
activates an antiviral response (35). Knockout of RIG-I will result in increased mortality (75).  
IAV can suppress the RIG-I activation using its NS1 protein, thus escaping the innate immunity. 
RIG-I activation also induces the production of inflammatory proteins which are mediated by 
NF-kB activation.   
IFN signaling: Influenza virus infection results in increased production of type 1 
interferon including interferon alpha and beta (IFN- α/β) which plays an important role in innate 
immunity by infected cells. Upon secretion,  type I interferon can act in an autocrine and 
paracrine fashion by binding to the IFN-α receptor (IFNAR) complex on the infected cells or on 
its neighboring cells respectively. This process, following signal transduction, leads to 
upregulation of INF-stimulated genes (ISGs), such as Protein Kinase R (PKR), 2’5’-
oligoadenylated synthetase (OAS), and Mx genes, which mediates the biological function of 
IFN, such as inhibition of viral replication, cellular growth inhibition and apoptosis to build a 
antiviral state and limit the viral replication and prevent the spread of invading viruses (63).  
Humoral response: The humoral response against influenza A viruses plays an 
important role in protecting a host from infection.  Neutralizing antibodies are mainly produced 
against the viral surface proteins HA, NA, and M2 (35). Among them, the HA-specific antibody 
is the most potent neutralizing antibody for disease prevention (16). The main antibody isotypes 
that can be detected during the primary influenza infection are IgA, IgM, IgG (16, 35). Secretory 
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IgA is secreted in the mucus of respiratory tract, protecting the local cells from being infected 
with influenza viruses.  IgM can be viewed as a sign of primary infection which peaks after two 
weeks; serum IgG together with IgA are predominant in secondary infection and provide long-
live protection against the same virus infection (16, 35, 75). This immunity can last for several 
years or even up to several decades, as indicated by the remarkable evidence that the neutralizing 
antibodies against 1918 influenza were found in the survivors 90 years after first exposure (82).  
The influenza A viruses outsmart the immune responses by their high genetic variability 
resulting from antigenic drift or antigenic shift.  Under the pressure of neutralizing antibody, the 
virus HA mutates its amino acid residues, resulting in the decreased efficiency or failure of the 
existing antibody (35).  
Cellular immunity: T cell mediated immune response is responsible for virus clearance 
in infected cells and for limiting virus spread in cooperation with antibodies (16) . Cytotoxic T 
lymphocytes (CTL) are recruited to infection sites and lyse or induce apoptosis of the infected 
cells (35). The viral targets for CTL are mainly the internal proteins, such as M1, NP, PA and 
PB2 proteins (16, 21, 35). CTL responses have been shown to display cross-protection between 
different subtypes of influenza A viruses (16, 19) 
 1.3.4 Prevention and treatment 
 1.3.4.1 Vaccination 
Currently, vaccination is still the most effective way to prevent and control influenza 
among humans and other species. Isolation of influenza virus from embryonated chicken eggs 
has enabled massive vaccine production since the 1930s. In the U.S., the current licensed human 
flu vaccine is trivalent inactivated (TIV) and live-attenuated influenza vaccine (LAIV) to combat 
seasonal and pandemic influenza outbreak (28). Because of the antigenic drift property when the 
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viruses go through point mutation during viral replication, vaccines for seasonal influenza are 
modified annually. A pandemic can begin through antigenic shift in which the gene segments 
reassort between different species, resulting in a dramatic change of the virus. Thus surveillance 
and prediction has to be done prior to vaccine production in anticipation of the next year’s strain 
of pandemic. Vaccination is suggested for every individual, especially for vulnerable populations 
which suffer complications from influenza, such as people older than 50 years or health care 
workers (16). Many systematic reviews and meta-analyses show that vaccination decreases the 
illness or mortality caused by influenza among different populations (17, 26, 30, 53, 78), 
indicating the substantial benefits of vaccination. Despite the general benefits of vaccination, it is 
not perfect. First, constant antigenic drift variants pose a challenge for any vaccine, as the virus 
goes through antigenic mutation very quickly; and mismatch between the changing virus and the 
vaccine can impair the vaccine effectiveness (11), resulting in less effective vaccine protection 
through vaccines or even complete failure of vaccine protection. Second, the time line for 
producing real-time protection via vaccination for an emerging pandemic is challenging because 
there is not sufficient time for massive vaccine production and delivery when a pandemic 
influenza strain emerges quickly.  
It is important to vaccine both humans and animals (especially pigs) since pigs play an 
important role in influenza reassortment. As previously noted, pigs serve as a “mixing vessel” in 
which  novel influenza strains can emerge, raising significant food safety and  public health 
concerns (44). The commercially available influenza vaccine used for swine worldwide is 
inactivated whole virus whose response to new strain emergence in time is still limited (45).     
New technology and research has been applied to improve the efficiency of many 
vaccines, such as DNA vaccine, subunit vaccine, vectored vaccine and vaccines with improved 
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adjuvants.  An ideal goal for a vaccine is to produce a universal flu vaccine to solve the problems 
that occur with the current vaccine situation.  
 1.3.4.2 Antiviral Drugs 
In addition to vaccination, antiviral drugs are an important method for the control and 
prevention of influenza infections. Two classes of licensed influenza antiviral drug agents are 
available in the United States: adamantanes and neuraminidase inhibitors (61).   
 1.3.4.2.1 Adamantanes  
Adamantanes such as amantadine and rimantadine were the first approved antiviral drugs 
for influenza treatment in clinics. By interfering with the function of the viral M2 protein, which 
is an ion channel for hydrogen ions to facilitate the viral RNP complex to dissociate from the 
matrix protein (M1), adamantanes can impact viral replication at an early stage. The therapeutic 
benefit of these drugs has been described as reduced duration of fever by one day and the 
prevention of clinical influenza cases up to 23% (31). Side effects associated with adamantane 
have been identified such as anxiety, depression, insomnia and gastrointestinal disorders (31, 
32). Besides these side effects, another important factor that has limited the use of adamantane 
has been the prevalence of drug-resistance mutations. A single substitution at one of five codons 
(L26F, V27A, A30V, A30T, S31N, and G34E) in the transmembrane region of the M2 protein is 
sufficient to result in drug resistance (18, 37, 81) The prevailing emergence of adamantine 
resistant strains has been reported worldwide since 2004 (61). Because of these reasons, the 
clinical use of adamantines is now discouraged.   
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 1.3.4.2.1 Neuraminidase Inhibitors 
Neuraminidase inhibitors function by inhibiting the Neuraminidase (NA) enzyme activity 
of the virus.  NA enzyme cleaves the N-acetyl sialic acid moieties and releases the budding 
influenza virions from the cell, allowing the virus to spread to other sites. In the United States, 
Zamavir and Oseltamivir (Tamiflu) are approved for both influenza prophylaxis and treatment. 
The FDA has also approved the use of Peramivir, an intravenous neuraminidase inhibitor for the 
treatment of patients with severe influenza (4).  The antiviral effect of Neuraminidase inhibitors 
have been demonstrated (2, 20, 28, 70). Nevertheless, there are also issues in the use of 
Nueraminidase inhibitor. In vitro studies have shown that viruses go through mutation in both 
NA and HA under the pressure of Neuraminidase inhibitors, resulting in drug resistance (1, 48). 
Thus the extensive use of Neuraminidase inhibitors for the prophylaxis and treatment of 
pandemic H1N1 can result in the emergence of drug-resistant variants (76). Resistance to 
Zanamivir is less frequent than resistance to Oseltamivir; however, whether this difference in 
drug resistance is because of the drug property or just because Zanamivir is simply less used than 
Oseltamivir still needs to be clarified (61).  
   1.4 Purpose of the Research 
             As previously noted, the currently applied methods for IAV prevention and treatment are 
vaccination and antiviral treatments. However, both methods have their limitations.  Vaccines 
can lose their efficiency to protect the host due to influenza viruses’ constant evolutionary 
adaptation through either antigenic drift or antigenic shift. Furthermore, the emergence of 
antiviral resistant strains causes the failure of antiviral drugs such as Amantadine and 
Oseltamivir.  
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Alferon N contains at least 14 subspecies of alpha interferon molecules and is a natural 
interferon alpha product derived from human leukocytes. This drug has been approved by the 
U.S. Food and Drug Administration for the treatment of refractory condylomata acuminata 
(genital warts).  The key issue that emerges from this literature review of influenza viruses is to 
investigate whether Alferon N is able to inhibit influenza A virus replication in cell cultures. 
Furthermore, it is necessary to explore the efficiency of using exogenous IFN-α treatment in vivo 
as an alternative approach to combat infection with influenza A viruses, especially in patients 
infected with influenza strains which are resistant to common antiviral treatments. 
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Chapter 2 - Materials and Methods 
 2.1 Viruses and Reagents 
 
Swine-origin pandemic H1N1 (Alb09; A/swine/Alberta/25/2009), isolated from Canadian 
pigs, was used in this experiment.  The genome of this virus exhibited 99.6%-100% identity at 
the nucleotide level with human isolated pandemic H1N1 (A/CA/04/09, CA09) (43). Alb09 was 
amplified in 9-day-old embryonated chicken eggs. Avian H9N2 (A/quail/Hong Kong/G1/97) 
was a gift by Dr. Peiris (University of Hong Kong) and generated in the Richt lab using a reverse 
genetic system and amplified on 9-day-old embryonated chicken eggs. Swine H3N2 
(A/swine/Tx98/4199-2/98) was amplified in MDCK cells. All viruses were titrated in MDCK 
cells by detection of Nucleoprotein (NP) protein in the cells after 72 hours infection via 
immunohistochemistry assay, using influenza NP protein specific monoclonal antibody. The 
virus stocks had titers of 10
6.5 
TCID50/ml, 10
8.5 
TCID50/ml, 10
7.5 
TCID50/ml in MDCK cells using 
the method of Reed and Muench for Alb09, H9N2, Tx98 respectively.  
Diluting solution: PBS with 0.05% Tween (w/v) (Acros, New Jersey, USA) and 1% BSA 
(w/v) (Sigma, St. Louis, MO); AEC diluet0.1M acetic acid mix with 0.1M sodium acetate at a 
ratio of 21:79 (v/v); AEC solution: 3-Amino-9-ethyl-Carbazole (AEC; sigma, St. Louis, MO) 
dissolved with dimethylformamide at a ratio of 4:1 (w/v). AEC substrate: AEC diluent mixed 
with AEC solution at a ratio of 19:1. 
 2.2 Cells and Alferon N 
Swine Testis (ST) and Madin-Darby canine kidney (MDCK) cells were cultured in 
minimum essential medium (MEM; Mediatech, Manassas, VA) with 5% fetal bovine serum 
(FBS; HyClone, Logan, UT), 1%  L-glutamine (Invitrogen, Grand Island, NY), 1% MEM 
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vitamins (Invitrogen, Grand Island, NY) and 1% antibiotics (Invitrogen, Grand Island, NY). For 
ST and MDCK cells, these virus infections were performed in an infection medium containing 
MEM, 0.3% bovine serum albumin (BSA; Sigma, St Louis, MO), L-glutamine (Invitrogen, 
Grand Island, NY), MEM vitamins (Invitrogen, Grand Island, NY), and 1% antibiotics 
(Invitrogen, Grand Island, NY). 
Adenocarcinomic human alveolar basal epithelial cells (A549) were cultured in 
Dulbecco’s modified eagle’s media (DMEM; Mediatech, Manassas, VA) with 10% fetal bovine 
serum (FBS; HyClone, Logan, UT) 1%  L-glutamine (Invitrogen, Grand Island, NY), 1% MEM 
vitamins (Invitrogen, Grand Island, NY) and 1% antibiotics (Invitrogen, Grand Island, NY). 
Virus infections using A549 cells were performed in an infection medium containing Opti-MEM 
(Invitrogen, Grand Island, NY), 0.2% bovine serum albumin (BSA; Sigma, St Louis, MO).   
The Alferon N injection (Hemispherx, New Brunswick, NJ) was provided by 
Hemispherx Biopharma, INC.. It is a natural interferon alpha product derived from human 
leukocytes which contains at least 14 subspecies of alpha interferon molecules that has been 
approved by the U.S. Food and Drug Administration in the treatment of refractory condylomata 
acuminata (genital warts).  Alferon N was diluted with infection media respectively for ST and 
A549 cells treatment before use.  
 2.3 Alferon N treatment 
Confluent ST and A549 cells were grown in 48-well plates. Immediately before Alferon 
N  treatment, the cells were washed with warm MEM (Mediatech, Manassas, VA) or opti-MEM 
(Invitrogen, Grand Island, NY)  and subsequently treated with 10000 U/well, 1000 U/well, 100 
U/well, 10 U/well of Alferon N (Hemispherx, New Brunswick, NJ) in 250 µl MEM containing 
0.3% bovine serum albumin (BSA; Sigma, St Louis, MO), L-glutamine (Invitrogen, Grand 
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Island, NY), MEM vitamins (Invitrogen, Grand Island, NY), and 1% antibiotics for ST cells and 
in Opti-MEM (Invitrogen, Grand Island, NY), 0.2% bovine serum albumin (BSA; Sigma, St 
Louis, MO) for A549 cells. For real-time RT-PCR, 4h, 8h, 16h, 24h treated cells were digested 
with Typsin-Versene mixture (Lonza, Walkersville, MD) until cells detached from the plates. 
The resulting cell suspension was centrifuged at 1200rpm for 5 minutes and cell pellets were 
collected and stored in -80°C for later use. For the cell viability test, four hours of Alferon N 
treated ST cells and 16 hours of Alferon N treated A549 cells were collected every 12 hours over 
48 hours period. Cells were detached from the plates by incubating with typsin-Versene mixture. 
Collected  cell suspension was mixed very well by pipetting up and down for several times and 
was stained with 0.4% trypan blue (Sigma, St Louis, MO); and live cells versus damaged cells 
were counted under a microscope using hemacytometer (Fisher, Pittsburgh, PA). For infection, 
cells were infected with A/swine/Alberta/25/2009, A/quail/Hong Kong/G1/97, 
A/swine/Tx98/4199-2/98 after incubated at 37°C, 5% CO2 for 4h, 8h, 16h, 24h with Alferon N. 
The cells were infected at a multiplicity of infection (MOI) of 0.01 and the final volume was 
500µl/well. Viruses were diluted in fresh infection medium supplemented with 1μg/ml TPCK [l-
(tosylamido-2-phenyl) ethyl chloromethyl ketone] trypsin (Worthington Biochemical, 
Lakewood, NJ). Supernatants were collected at 12, 24h, 36h, 40h, 48h post infection and stored 
at -20°C.   
 2.4 Titrations 
Quadruplicate titration of each supernatant sample was performed in 96-well plates in 
tenfold serial dilutions from 10
-1
 to 10
-8
. The dilutions were transferred to confluent monolayers 
of MDCK cells in 96-well plates which were washed once using blank MEM (Mediatech, 
Manassas, VA) or Opti-MEM (Invitrogen, Grand Island, NY) before titration.  The cells were 
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then incubated at 37°C, 5% CO2 for 3 days; and the titer of virus in the supernatants was 
evaluated by detecting the cytopathic effect (CPE) induced by the virus in the cell culture every 
day. At 72 hours post-infection, cells were fixed with methanol at room temperature for ten 
minutes and immunohistochemistry was performed to detect viral NP protein in the infected 
cells. First, mouse anti-nucleoprotein (NP) serum (ATCC#HB-65) diluted by diluting solution 
(see above “viruses and reagents”) at a ratio of 1:500 was added to the cells and incubated for 30 
minutes. Second, after washing plates with washing medium (PBS, 0.05% Tween 20 (Acros, 
New Jersey, USA)), cells were incubated with Polyclonal Rabbit Anti-Mouse 
Immunoglobulins/HRP (sigma, St Louis, MO) which was diluted by diluting solution at a ratio 
of 1:300 and incubated for 30 minutes.  Finally, after washing the plates 3 times with the 
washing medium, cells were incubated with AEC dilution (see above “viruses and reagents”) 
containing 1% Hydrogen Peroxide (sigma, St. Louis, MO) for 45 minutes before stopping the 
reaction with distilled water. Positive signals were detected as red color under the microscope. 
The 50% tissue culture infective dose (TCID50)/ml was calculated by the Reed and Muench 
method (38). The detection limit for the virus load was 10 TCID50/ml. 
 2.5 RNA extraction 
RNA was extracted using RNeasy® Mini kit (Qiagen, Maryland, USA). Briefly, cell 
pellets were thawed thoroughly and disrupted by adding Buffer RLT, then homogenized with 1 
volume of 70% ethanol. Samples were centrifuged through RNeasy spin column for 15sec at 
13,000rpm. The RNA was eluted by adding RNase-free water directly to the spin column 
membrane after washing the membrane with RW1 (reagent in kit) once and RPE (reagent in kit) 
twice. RNA concentration was detected using NanoDrop 1000 spectrophotometer (Thermo 
Scientific) and diluted to 100ng/µl using RNase-free water. 
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 2.6 Quantitative RT-PCR 
Quantitative RT-PCR was established to detect the Interferon Stimulated Genes (ISG)-
Mx, 2’5’OAS1. The following primers used were: Mx Forward: 5’-
CGCATCTCCAGCCACATCC-3’; Mx Reverse: 5’AGCCGCTCCTTCAGGAACTT-3’. 2’5’ 
OAS1 Forward: 5’-ACCAAGCTGAAGAGCCTCATCC-3’; 2’5’ OAS1 Reward:5’- 
GCTCCCATGCATAGACTGTCAG-3’and control housekeeping gene (β-actin) Forward: 5’-
CTCGATCATGAAGTGCGACGT-3’, β-actin reverse: 5’-
GTGATCTCCTTCTGCATCCTGTC-3’. The primers were designed to detect conserved regions 
within Mx, OAS1 and β-actin of sus scrofa and homo sapiens. Primers (IDT, San Jose, CA) were 
diluted in distilled water to 25pmol for final use. Quantitative RT-PCR was performed using 
QuantiFast SYBR Green RT-PCR Kit (Qiagen, Maryland, USA) on the SmartCycler (Cepheid, 
Sunnyvale, CA) in a total volume of 25 µl containing 1 µl of each primers, 0.25 µl QuantiFast 
RT Mix, 12.5 µl 2X QuantiFast® SYBR® Green RT-PCR Master Mix, 1 µl template RNA, 9.25 
µl RNase-free water. The cycling program consisted of a reverse transcription step at 50°C for 
10min, PCR initial activation step at 95°C for 5min, followed by 40 cycles of 95°C for 10sec, 
60°C for 30sec.  Real time RT-PCRs for housekeeping gene (β-actin) were run in parallel with 
target genes. Gene mRNA level (ΔCt) was normalized by using Ct value of target genes 
subtracting the Ct value of β-actin. The ΔCt value of Alferon N non-treated sample was than 
subtracted from the Alferon N treated sample to obtain ΔΔCt. The fold change of target genes in 
response to Alferon N treatment was calculated by 2
-ΔΔCt
.  
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 2.7 Statistical Analysis 
Statistics are expressed as the mean and standard error for each mean. Results are 
represented as the mean of three independent experiments under each condition.  A two-tail t-test 
was used to determine the differences between means, and a significant difference was 
considered as P<0.05.  
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Chapter 3 - Results 
 3.1 ST and A549 cells are susceptible to influenza virus infections 
 In order to study the susceptibility of ST cells and A549 cells to influenza A virus 
infection and replication, both cell types were infected with swine-origin pH1N1 (A/swine/ 
Alberta/25/2009), Avian H9N2 (A/quail/Hong Kong/G1/97) or Swine H3N2 (A/swine/Tx98/ 
4199-2/98) respectively at a MOI of 0.01. Supernatants were collected 48 hours post infection 
and titrated in MDCK cells. All three strains of influenza A viruses replicated in ST cells at 48h 
pi; as shown in Figure 3-1, Pandemic H1N1 replicated to 5.7 ± 0.15 log TCID50/ml; Swine H3N2 
replicated to 5.8 ± 0.25 log TCID50/ml; Avian H9N2 replicated to 6.33 ± 0.17 log TCID50/ml.   
As shown in Figure 3-2 below, in A549 cells both H9N2 and H3N2 reached to titers around 7 
logTCID50/ml (Swine H3N2 replicated to 6.8 ± 0.11 log TCID50/ml; Avian H9N2 replicated to 
7.5 ± 0.29 log TCID50/ml). Pandemic H1N1 also infected A549, albeit with a lower virus titer of 
5.18 ± 0.18 log TCID50/ml. These data show that ST cells and A549 cells are susceptible to 
infection and replication of the influenza A viruses used in this experiment. 
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Figure 3-1 ST cells are susceptible to influenza A viruses infection 
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Figure 3-2 A549 cells are susceptible to influenza A viruses infection 
 
 
 3.2 Pretreatment with Alferon N Inhibits Influenza A Virus Replication in ST 
cells 
 3.2.1 Alferon N Inhibits Pandemic H1N1 
            To examine the antiviral effect of Alferon N against Pandemic H1N1 infection and 
replication, confluent ST cells in 48-well plates were treated with 10000 IU/well, 1000 IU/well 
and 500 IU/well of Alferon N for four hours prior to infection with pH1N1 (A/swine/Alberta/25/ 
2009) at a MOI of 0.01. Viral titer was determined 48 hours after infection.  Reduced viral titer 
was observed in all Alferon treated samples compared to mock treated samples. In mock-treated 
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ST cells, the virus replicated to 10
6.5 
TCID50/ml at 48h pi, whereas viral titer was 10
3.33
 
TCID50/ml in 1000 IU/well Alferon N treated samples or even lower in the other Alferon N-
treated cells, as set out in Figure 3-3. The results showed that Alferon N inhibited pH1N1 
replication in ST cells. 
 
Figure 3-3 Alferon N inhibits pH1N1 replication in ST cells 
 
  
 
 
                     
           To examine the antiviral effect of Alferon N against Pandemic H1N1 infection and its 
replication, confluent ST cells in 48-well plates were treated with 10000 IU/well, 1000 IU/well, 
100 IU/well, 10 IU/well of Alferon N for four hours prior to infection with pH1N1 
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(A/swine/Alberta/25/2009) at a MOI of 0.01.  Virus replication kinetics were measured over 48 
hours. As shown in Figure 3-4, at 12h pi viruses with similar titers were detected from the mock-
treated and 10 IU Alferon N treated samples, while no viruses were detected from samples 
treated with 100 IU or higher doses of Alferon N. At 24h pi, there was approximately 1 log 
TCID50/ml of virus detected in all Alferon N treated samples  which was significantly reduced 
compared to in mock treated cell cultures which was 4.44 log TCID50/ml (P<0.05).  At 36h pi, 
there was more than 1.5 log TCID50 difference in virus titer between the Alferon N treated and 
mock treated groups, while virus replication was significantly reduced in all Alferon N treated 
samples compared to mock treated samples (P <0.05). Virus titers reached a similar titer in 10 IU 
of Alferon N-treated samples as the mock treated samples at 48h pi; virus titer of samples treated 
with higher units of Alferon N was significantly reduced (P<0.05) up to more than 2.5 log 
TCID50 than that of mock treated samples. These results indicated that Alferon N is able to 
inhibit replication of the pH1N1 virus in ST cells and that 100 units of Alferon N is the minimal 
amount for efficient inhibition of  pH1N1 virus replication. 
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Figure 3-4 Dose dependent inhibition effect of Alferon N on the replication of Pandemic      
H1N1 in ST cells 
 
 
 3.2.2 Alferon N Inhibits Avian H9N2 
            Avian H9N2 was also used to determine the antiviral effect of Alferon N on avian 
influenza virus infection in ST cells. Confluent ST cells in 48-well plates were treated with 
10000 IU, 1000 IU, 100 IU, 10 IU of Alferon N before infection with Avian H9N2 
(A/quail/Hong Kong/G1/97) at a MOI of 0.01. Virus growth kinetics were measured over 48 
hours. As show in Figure 3-5, reductions in virus titers were observed in Alferon N treated 
samples between 12h pi and 48h pi. At 12h pi, more than 1 log TCID50 reduction in virus titer 
was observed in 100 IU or a higher dose of Alferon treated samples compared to mock treated 
samples, with no virus was detectable in 10000 IU treated samples. The virus titer in 10 IU of 
31 
 
Alferon N treated samples was similar to mock treated samples (P<0.05).  At 24h pi, virus 
replicated to 10
5.4 
TCID50/ml in mock treated cells, but only to 10
4.3 
TCID50/ml in 10 IU Alferon 
N treated cells. 100 IU of Alferon N treatment led to a reduction of 1.9 log TCID50 compared to 
controls (P <0.05); 1000 IU and 10000 IU of Alferon N treatment resulted in a virus titer 
reduction of up to 3.7 log TCID50 at this time point (P <0.05). A more obvious inhibition effect 
of Alferon N was found at 36h pi, as described below. At this time point, virus replicated to 10
7 
TCID50/ml in mock treated cells; and a significant reduction of virus titers was found in all 
Alferon N treated cells (P<0.05) compared to controls. 10 IU of Alferon N treatment resulted in a 
virus titer reduction of 1.5 log TCID50 (P <0.05), while 100 IU and 1000 IU of Alferon N 
treatment resulted in a reduction of 3 and 5.5 log TCID50, respectively (P <0.05). Meanwhile, no 
virus was detectable in the supernatant of 10000 IU treated samples. Virus replicated to a similar 
titer in 10 IU of Alferon N treated samples as in the mock treated samples at 48h pi; and the virus 
titer of samples treated with higher units of Alferon N was significantly reduced up to more than 
3 log TCID50 compared to that of mock treated samples (P<0.05). Thus enhanced inhibition was 
observed when a higher dose of Alferon N was applied, with 10000 IU of Alferon N treatment 
leading to undetectable virus in the supernatants. These results demonstrate that Alferon N is 
able to inhibit replication of avian H9N2 virus in ST cells in a dose dependent manner with 100 
units of Alferon N the cutline for efficient inhibition of avian H9N2 virus replication. 
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Figure 3-5 Dose dependent inhibition effect of Alferon N on the replication of Avian H9N2 
in ST cells 
 
 
 3.2.3 Alferon N Inhibits Swine H3N2 
To further explore the broad spectrum of antiviral potential of Alferon N against IAV 
infection, swine H3N2 virus was then used in this experiment. Confluent ST cells in 48-well 
plates were treated with 10000 IU, 1000 IU, 100 IU, 10 IU of Alferon N before infection with 
swine H3N2 (A/swine/Tx98/4199-2/98) at a MOI of 0.01. Virus growth was measured over 48 
hours. As shown in Figure 3-6, at 12h pi, no reduction of virus titers was found in 10 and 100 IU 
of Alferon N treated samples compared to mock treated ones. Furthermore, viruses were barely 
detectable in the supernatant of 1000 IU or 10000 IU treated cells. At 24h pi, the virus replicated 
to 10
5.5 
TCID50/ml in mock treated cells, while 10 IU of Alferon N treatment reduced the virus 
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titer to 10
4.0 
TCID50/ml (P<0.05). Higher doses of Alferon N treatment resulted in virus titer 
reduction of up to 3.9 log TCID50, significantly inhibiting the virus growth (P<0.05) compared to 
mock treated cells. 10 IU of Alferon N treatment did not reduce the virus titer at 36 and 48h pi, 
while 100 IU of Alferon N treatment led to approximately 1 log unit of viral titer reduction 
compared to controls at these time points, respectively. 1000 IU or 10000 IU of Alferon N 
treatment resulted in viral titer reduction of up to 3 log TCID50 at 36h pi (P<0.05). There was a 3 
log TCID50 reduction in 1000IU treated samples and a 5 log TCID50 reduction in 10000IU treated 
samples at 48h pi (P<0.05). These results suggest that Alferon N can inhibit replication of swine 
H3N2 virus in ST cells. The inhibition effect is dose dependent with 100 units of Alferon N the 
minimum dose for efficient inhibition of the swine H3N2 virus replication. 
 
34 
 
Figure 3-6 Dose dependent inhibition effect of Alferon N on the replication of Swine H3N2 
in ST cells 
 
 
  
  
 
3.3 Treatment of Alferon N for 4h Inhibits IAVs Replication in A549 cells 
 
In addition to ST cells as an in vitro study model, A549 (human lung adenocarcinoma 
epithelial) cells were also used to determine the antiviral potential of Alferon N against IAVs 
infection and replication. Confluent A549 cells in 48-well plates were treated with 10000 IU, 
1000 IU, 100 IU, 10 IU of Alferon N before infection with pandemic H1N1, avian H9N2, swine 
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H3N2 at a MOI of 0.01. Supernatants were collected 36 and 48 hours post-infection; and virus 
titers were determined by titration on MDCK cells. 
 3.3.1 Alferon N Inhibits Pandemic H1N1 
As shown in Figure 3-7A, pandemic H1N1 replicated to 10
4.7 
TCID50/ml in mock treated 
A549 cells. 10 IU of Alferon N treatment led to a virus titer reduction of 0.6 log TCID50, while 
higher doses of Alferon N treatment (100 IU, 1000 IU and 10000 IU) resulted in approximately 1 
log TCID50 virus titer reduction compared to mock treatment. At 48h pi (Figure 3-7B), there was 
approximately 1 log TCID50 difference between 10 IU, 100 IU Alferon treated samples and 
mock treated samples. Virus replicated to a titer of 3.5 log TCID50/ml in 1000 IU and 10000 IU 
Alferon N treated cells, which was 2 log TCID50 lower than in mock treated cells (P<0.05). 
These results demonstrated that Alferon N can inhibit the replication of pandemic H1N1 in A549 
cells, albeit to a lesser extent than in ST cells. 
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Figure 3-7 Effect of Four hours of Alferon N treatment of A549 cells on the replication of 
Pandemic H1N1     
          
 
 
 
 3.3.2 Alferon N Inhibits Avian H9N2 
As shown in Figure 3-8A, at 36h pi, avian H9N2 replicated to 6.4 log TCID50/ml in 
mock treated A549 cells and virus titer reduction was observed in Alferon N pretreatment cells. 
10 and 100 IU of Alferon N pretreatment resulted in 0.8 and 1.4 log TCID50 reductions compared 
to mock treatment, respectively, while 1000 IU of Alferon N treatment led to 2 log TCID50 
reduction compared to mock treatment. Virus replicated to the lowest titer (10
3.3
TCID50/ml), 
which is 3.2 log lower than mock treated samples at 36h pi (P<0.05). At 48h pi (Figure 3-8B), 
maximum inhibition effect was observed in 10000 IU of Alferon N treated samples, virus 
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replicated to1.6 log TCID50 lower than in mock treated samples. There was  approximately 1.3 
log TCID50 reduction between 1000 IU Alferon N treated samples and mock treated ones, 
whereas only 0.6 log TCID50 reduction was observed between 100 IU or 10 IU Alferon N treated 
and mock treated samples. This data suggested that Alferon N can inhibit the replication of 
pandemic H1N1 in A549 cells, albeit to a lesser extent than in ST cells. Interestingly better 
inhibition was achieved at 36h pi compared with 48h pi. 
 
Figure 3-8 Effect of four hours of Alferon N treatment of A549 cells on the replication of 
Avian H9N2 
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 3.3.3 Alferon N Inhibits Swine H3N2 
As shown in Figure 3-9A, at 36h pi, virus replicated to the similar level with control in 10 
IU and 100 IU of Alferon N treated samples. There was a 0.6 log TCID50 difference between1000 
IU of Alferon N treated samples and mock treated samples. A significant inhibition was observed 
in 10000 IU treated samples (P<0.05), where the virus titer was 1.5 log TCID50 lower than in 
mock treated samples.  At 48h pi (Figure 3-9B), 10000 IU of Alferon N treatment led to 1 log 
TCID50 reduction of virus titer compared to mock treatment (P>0.05). There were no obvious 
differences between the other doses of Alferon N treatment and mock treatment. These results 
showed that a much higher dose is required to reach inhibition against swine H3N2 in A549 cells 
than in ST cells for 4 hours of Alferon N pretreatment. 
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Figure 3-9 Effect of Four hours of Alferon N treatment of A549 cells on the replication of 
Swine H3N2 
 
 
 3.4 Longer Time of Alferon N Pretreatment Enhances the Antiviral Potential 
in A549 Cells 
 
As can be seen in chapter 3.3, the inhibition of 4 hour Alferon N of A549 cells 
pretreatment is not as obvious as was observed in ST cells. Therefore, it was appropriate to 
consider whether a longer time of Alferon pretreatment could enhance the antiviral effect. In 
order to answer this question, confluent A549 cells in 48-well plates were treated with 1000 IU 
of Alferon N before infection for 4, 8, 16 and 24 hours. Cells were then infected with pandemic 
H1N1, avian H9N2 or swine H3N2 at a MOI of 0.01. Supernatants were collected 40h pi and 
virus titers were determined by titration in MDCK cells. As shown in Figure 3-10, pandemic 
H1N1 in mock treated cells replicated to 10
4.3 
TCID50/ml at 40h pi, while 4 hour Alferon 
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pretreatment resulted in around 1.4 log TCID50 compared to mock treatment (P<0.05). Enhanced 
viral titer reduction was observed in longer Alferon N pretreated samples. The virus titers in 
longer Alferon N (more than 8 hours) treated samples were more than 2.5 log TCID50 lower than 
in controls (P<0.05). 
Avian H9N2 replicated to 10
5.8 
TCID50/ml in mock treated samples at 40h pi. Virus 
replication was significantly inhibited in Alferon N treated samples (P<0.5) compared to mock 
treated samples. An enhanced inhibition effect was observed if a longer time of Alferon N 
pretreatment was applied. The strongest inhibition was reached in 16 hours of Alferon N treated 
samples with up to a 5 log TCID50 reduction of virus titer compared to mock treated samples. 
Swine H3N2 replicated to 10
6 
TCID50/ml in mock treated cells at 40h pi. Virus titer was 
reduced to 10
5.3 
TCID50/ml in 4h Alferon N (P<0.05). There was a even more significant 
difference of virus titer between eight or more hours Alferon N pretreated samples and mock 
treated sample (P<0.05), while 8 and 16 hours of Alferon N pretreatment led to up to 2.2 and 2.4 
log TCID50 reduction respectively compared to mock treatment. The highest viral titer reduction 
was achieved in 24 hours with Alferon N pretreated samples which were up to 3.2 log TCID50 
reduction.  
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Figure 3-10 Time effect of Alferon N treatment on the inhibition result achieved in A549 
cells  
 
 
 
These data suggested that a longer time of Alferon N pretreatment can enhance the 
antiviral effect in A549 cells—an important issue that is investigated further below. 
 
 3.5 16 Hours of Alferon N Pretreatment Inhibits Influenza A Virus 
Replication in A549 Cells 
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To explore the antiviral effect of longer time Alferon N pretreatment against IAV 
infections in A549 cell, confluent A549 cells in 48-well plates were treated with 1000 IU, 100 IU 
and 10 IU for 16 hours before infection with pandemic H1N1, avian H9N2 or swine H3N2 at a 
MOI of 0.01. Virus replication kinetics were monitored over 48 hours by titration in MDCK 
cells. 
 3.5.1 Pandemic H1N1 Replication after 16 Hours of Alferon N Pretreatment 
As shown in Figure 3-11, at 12h pi, pandemic H1N1 replicated to 10
2.9 
TCID50/ml in 
mock treated A549 cells; virus reduction was found at 1000 IU treated samples, which were 0.5 
log TCID50 lower than mock treated ones. At 24h pi, 10 IU treatment resulted in 0.3 log TCID50 
reduction, while 100 IU and 1000 IU treatment result in approximately 1 log TCID50 reduction 
compared to mock treatment (P<0.05). Inhibition was observed at 36h pi, when 1 log TCID50 
reduction was found in 10 IU treated samples, and approximately 2 log TCID50 reduction was 
observed in 100 and 1000 IU treated samples compared to mock treated controls (P<0.05). 
Inhibition of 1 and 2 log TCID50 was found in 10 IU and 100 IU Alferon N pretreated samples at 
48h pi (P<0.05); and 1000 IU of Alferon N pretreatment led to a reduction of 2.5 log TCID50 in 
virus titer compared to the mock treatment (P<0.05). These results indicated that pandemic 
H1N1 replication was susceptible to inhibition by 16 hours Alferon N pretreatment as low as the 
dose of 10 IU. 
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Figure 3-11 Dose dependent inhibition effect of 16 hours Alferon N treatment on the 
replication of Pandemic H1N1 in A549 cells 
 
 3.5.2 Avian H9N2 Replication after 16 Hours of Alferon N treatment 
As shown in Figure 3-12, pandemic H1N1 replicated to 10
2.9 
TCID50/ml in mock treated 
A549 cells. Furthermore, pretreatment with Alferon N for 16 hours reduced the virus titer from 
0.7 to 1 log TCID50 depending on the dose applied at 12h pi. At 24h pi, virus replicated to a 
similar titer in 10 IU treated samples with mock treated samples. Significant virus titer reduction 
was observed in 100 IU and 1000 IU treated samples with titers 2 and 2.5 log TCID50 lower than 
control samples (P<0.05). A 10 IU treatment led to a titer reduction of 1.1 log TCID50 at 36h pi 
compared to mock treatment, while 100 IU and 1000 IU of Alferon N treatment resulted in 2.5 
and 4.8 log TCID50 of virus titer reduction compared to mock treatments. At 48h pi, virus 
replicated to 10
6.6 
TCID50/ml in 10 IU treated cells, which was 0.9 log TCID50 lower than mock 
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treated cells. 2.3 and 3.5 log TCID50 reductions were found in 100 IU and 1000 IU treated 
samples respectively compared to mock treated controls.  These results indicate that avian H9N2 
replication was susceptible to inhibition by 16 hours of Alferon N pretreatment with a dose as 
low as 100 IU. 
 
Figure 3-12 Dose dependent inhibition effect of 16 hours Alferon N treatment on the 
replication of Avian H9N2 in A549 cells 
 
  
 
 3.5.3 Swine H3N2 Replication after 16 Hours of Alferon N Pretreatment 
As shown in Figure 3-13, there were no observed differences between mock controls and 
10 IU of Alferon N treatments from 12 to 48 h pi. There was no difference of virus titer between 
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100, 1000 IU Alferon treated samples and mock treated controls at 12h pi. At 24h pi, 100 IU 
Alferon N treatment led to 0.9 log TCID50 reduction compared to mock treatment, while 1000 IU 
Alferon N significantly reduced virus replication by reducing virus titer up to 2 log TCID50 
compared to mock treatment (P<0.05). Similar results were found at 36h pi with at 24h pi for 
100 IU and 1000 IU Alferon N treatment compared to its mock treatment respectively. At 48h pi, 
virus replicated to the same titer (10
2.9 
TCID50/ml) in 100 and 1000 IU treated cells which were 
significantly lower than in mock treated cells (P<0.05). These results demonstrated that swine 
H3N2 replication was susceptible to inhibition by 16 hours of Alferon N pretreatment at as low a 
dose as 100 IU starting at 48h pi. 
 
 
Figure 3-13 Dose dependent inhibition effect of 16 hours Alferon N treatment on the 
replication of Swine H3N2 in A549 cells 
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 3.6 Cellular toxicity of Alferon N  
To determine the cellular toxicity of Alferon N, cell viability assays were performed in 
both ST and A549 cells. Generally, both cells were treated with 10000 IU/well, 1000 IU/well, 
100 IU/well, 10 IU/well of Alferon N for 48 hours. Cells were collected every 12 hours and 
mixed with 0.4% trypan blue. Viable versus nonviable cells were counted under the microscope 
using a hemacytometer. As shown in Figure 3-14 (A), there was no obvious cellular toxicity in 
the ST cells treated with different doses of  Alferon N; the 10000 IU treated samples had the 
highest nonviable cell rate (from 1.6% to 3.6%) when compared to controls (1.1% to 2.3%), 
however, the difference was not significant (P>0.05). As shown Figure 3-14 (B), no cellular 
toxicity was detected in Alferon N treated A549 cells; the nonviable cell rate in 10000 IU 
Alferon N treated samples was around 5% (from 3.2% to 5.2%) which was similar to the cellular 
toxicity in mock treated controls (from 2.8% to 5.1%). There was no significant difference 
between Alferon N treated samples and controls (P>0.05). These data indicate a low cellular 
toxicity for Alferon N employing the concentrations used in the above described experiments.  
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Figure 3-14 Cellular toxicity of Alferon N in ST and A549 cells 
 
3.7 Analysis for Antiviral Gene Expression under 1000 IU Alferon N 
Treatment in ST and A549 Cells 
 
To explain the antiviral effect resulting from Alferon N pretreatment and the disparity of 
response to treatment between the two cell lines, confluent ST cells and A549 cells were lysed 
and collected after treatment with 1000 IU Alferon N for 4, 8, 16 and 24 hours. RNA was 
extracted from the samples, and real time RT-PCR was performed to examine the expression of 
Interferon Stimulated Genes (ISGs) Mx1/A (defined as Mx1 in swine and MxA in humans) and 
OAS1. Figure 3-15 (blue bar) showed that Mx1 expression was ten-fold higher in four hour 
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treated ST cells compared to mock treatment. An increasing trend for the upregulation of this 
gene was observed if ST cells were treated for a longer time. The highest Mx1 gene expression 
in ST cells was found in 24 hour Alferon N treated samples, which were approximately 40 fold 
up-regulated compared to controls. In A549 cells, MxA gene was enhanced 40 fold in four hour 
Alferon N treated samples compared to mock treatment. Longer time of treatment resulted in 
higher MxA expression in A549 cells. Up to 298 fold upgrade of MxA gene expression was 
observed in 24 hour Alferon N treated A549 cells compared to mock treatment (Figure 3-15, red 
bar). When comparing gene up-regulation between ST cells and A549 cells under the same 
treatment condition, Mx1/A gene expression was upregulated more in Alferon N treated A549 
cells than in ST cells. 
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Figure 3-15 The relative up-regulation of Mx1/A mRNA due to Alferon N treatment in ST 
and A549 cells
 
 
OAS1 gene expression was upregulated dramatically in Alferon N treated ST cells, with 
the highest fold change in 16 hour Alferon N treated samples, which were up to 480 fold higher 
than in mock treated controls (Figure 3-16, blue bar). In A549 cells (Figure 3-16, red bar), OAS1 
was also upregulated by Alferon N treatment, with maximum up-regulation of 32 fold found in 
the 16 hour Alferon N pretreated samples. OAS1 was enhanced to a significant level during 
treatment in ST cells compared to A549 cells. When upregulation was compared between ST 
cells and A549 cells, OAS1 gene expression was upregulated more in Alferon treated ST cells 
than in A549 cells under the same conditions. 
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Figure 3-16 The relative up-regulation of OAS1 mRNA due to Alferon N treatment in ST 
and A549 cell 
 
 
             
            In summary, ST cells and A549 cells were shown to sustain replication and infection of 
multiple influenza A viruses and were susceptible to the pre-treatment of Alferon N. The 
replication of different subtypes of IAVs was inhibited in a dose dependent manner after 
pretreatment of Alferon N: four hours of pretreatment was sufficient for the antiviral effect of 
Alferon N in ST cells, whereas a longer time of pretreatment was needed for detectable 
inhibition in A549 cells. The ISGs, such as Mx1/A and OAS1, contributed to the antiviral effect; 
and the different responses to Alferon N treatment could explain the different responses between 
ST cells and A549 cells.   
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Chapter 4 - Discussion and Conclusions  
 
Influenza has been a public health threat for over a century throughout the world. The 
evolution and variability of influenza viruses create significant hurdles for treatment and 
prevention. The 2009 pandemic H1N1 influenza was the first pandemic outbreak in the 21
st
 
century. It was a novel reassorted influenza virus with genes introduced from different avian, 
human and swine influenza viruses (58). Swine serve as important mixing vessels, mediating 
such reassortment from different species of influenza viruses. After adaptation in pigs, these 
viruses could infect humans, resulting in pandemic emergence. Attention has been focused on 
the avian H9N2 virus as a possible cause of a future pandemic, since this avian virus is now 
endemic in poultry and has been shown to infect both humans and pigs. Moreover, the avian 
H9N2 A/quail/Hong Kong/G1/97 was shown to share the same six internal genes with the lethal 
H5N1 virus which has caused disease in animal and human disease since 1997 (40).  
To investigate novel antiviral drugs in addition to current methods for better preparing for 
the next pandemic, I studied the growth of pandemic H1N1, avian H9N2 and swine H3N2 
influenza viruses after pretreatment with the FDA approved drug Alferon N (human interferon 
alpha).  My experiments demonstrated that pretreatment of swine and human cell lines with 
Alferon N can inhibit the growth of different subtypes of influenza A viruses. Alferon N 
pretreatment presented a broad spectrum of inhibition effects on different subtypes of Influenza 
A Viruses, including pandemic H1N1, swine H3N2 and avian H9N2. The experimental results 
also demonstrated that these inhibition effects are related to the upregulation of Interferon 
Stimulated Genes (ISGs) such as Mx and OAS1; and the disparity of response between cell lines 
52 
 
can result from the differential up-regulation levels of these genes after interferon alpha 
pretreatment.  
A549 cells have been used previously as a human lung cell model for influenza A viruses 
infection, because human lung cells are the primary target for influenza infection and A549 cells 
generate  the complete signaling pathway associated with innate immunity upon influenza virus 
infection (62, 71). I demonstrated here that pandemic H1N1, avian H9N2 and swine H3N2 can 
readily infect both a swine cell line and a human cell line; however pandemic H1N1 replicated to 
a lower level in human A549 cells compared with other subtypes and with its replication in ST 
cells.  This finding underlines the susceptibility of both swine and humans to different species of 
influenza virus infections and underscores the threat of novel influenza strain emergence by 
reassortment when two different strains infect the same host.  All three subtypes of influenza 
viruses replicated to a similar level in ST cells, including pandemic H1N1, which supported the 
theory that pigs can serve as mixing vessels for influenza infection. Interestingly, the swine 
origin pandemic H1N1 replicated to a lower level in human A549 cells compared with swine ST 
cells, likely because this pandemic H1N1 was a swine isolated strain which is better adaptive to 
swine than to human.  
This research demonstrated that the replication of pandemic H1N1, avian H9N2, swine 
H3N2 was susceptible to pretreatment with Alferon N in a dose dependent manner, with an 
effective dose as low as 100 IU in ST cells. The broad spectrum of the antiviral effect of 
interferon alpha was similar to results from previous studies (25, 51). Furthermore, in this 
research, I found that a similar effect of pretreatment of Alferon N could be achieved in human 
A549 cells; however this effect required longer treatment time, such as 16 hours. Interferon alpha 
is the first line of innate immunity to combat influenza virus infection. Upon infection, cells will 
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secrete interferon to alert themselves and neighboring cells to induce the expression of ISGs 
which together will result in protection from the virus. The pathogenicity of influenza A viruses 
are substantially controlled by the interferon system. Exogenous interferon alpha could induce 
the expression of many ISGs. Upon binding to the type I interferon receptor, interferon alpha 
activates the JAK/STAT pathway. The phosphorylated STAT1 and STAT2 proteins form a 
heterodimer which then associates with IFN-regulatory factor 9 (IRF-9). The new heterotrimer 
translocates to the nucleus and binds to ISRE (interferon stimulated response element) which 
resides in the promoter region of many ISGs and enhances the transcription of these genes (63).  
The upregulation and expression of cellular ISGs establishes the antiviral status of the host. 
Previous studies have shown that Mx and OAS play primary roles in mediating responses to 
foreign antigens (23, 62). Mx proteins (Mx1and Mx2 in swine, MxA and MxB in humans) are 
interferon induced GTPase involved in intracellular vesicle trafficking (27). MxA and Mx1 
localize in cytoplasm and possess strong capacity to inhibit the replication of influenza A virus 
via interfering with different steps of virus life cycle (27, 52). Human MxB is found both in 
nucleus and cytoplasm but fails to display antiviral function (50); Porcine Mx2 localizes in the 
nucleus and has been shown to possess antiviral activity against influenza viruses (52). By 
interacting with viral RNP proteins such as PB2 and NP, MxA or Mx1 can block the trafficking 
of viral proteins between cytoplasm and nucleus, resulting in the inhibition of viral transcription 
(63); The endocytic trafficking of incoming influenza A virus particles can also be blocked by 
porcine Mx1 (60). OAS proteins help synthesize 2’,5’-ogligoadenylates which will activate 
latent RNaseL, leading to RNA degradation, thus inhibiting the viral replication (63). The results 
in this study showed upregulation of Mx1/A and OAS1 in both ST cells and A549 cells, however 
the time course and quantity of upregulation is different between the two cells with MxA being 
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higher in A549 cells and OAS1 being higher in ST cells. The upregulation of both genes 
correlated with the decreased viral growth after Alferon N pre-treatment in both cells. In future 
experiments it would be interesting to study whether or not a longer time of Alferon N treatment 
or repeated Alferon N pretreatment would increase antiviral ability in cells. The different 
responses of cells following Alferon N treatment could be explained by the different levels of 
ISG gene expression with Alferon N treatment between the two cell lines. The rapid induction of 
OAS1gene expression in ST cells rather than in A549 cells after 4h of Alferon N treatment might 
account for the better inhibition effect in ST cells under these conditions. It still needs to be 
determined whether other ISGs may play a role in combating influenza A viruses and account for 
the different response in these two cell lines after Alferon N treatment.   
This research demonstrated that to counteract the interferon system, influenza A viruses 
have adapted methods to ensure a successful infection in the host. This interferon antagonizing 
function is mediated mainly by the nonstructural protein (NS1) through blocking the activation 
of interferon regulatory factor 3 (IRF3) and post translational processing of cellular mRNA (33). 
It has been shown that different NS1 genes will exhibit different capacities to counter the 
interferon system, thus resulting in different levels of pathogenicity (33) . Further, replication of 
viruses lacking interferon antagonistic NS1 gene have been shown to be significantly reduced 
(34). In this study, under the same conditions of IFN treatment, swine H3N2 replicated to a 
higher titer than either pandemic H1N1 or H9N2 especially in A549 cells, suggesting swine 
H3N2 expresses a NS1 protein with a stronger interferon antagonist compared with the other two 
strains. A previous study showed that a lethal H5N1 virus was  resistant to the exogenous 
interferon treatment in vitro due to a glutamic acid at position 92 of its NS1 protein (66). 
However, none of the viruses in this experiment possess glutamic acid at position 92 of their 
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NS1 proteins, suggesting the interferon resistance of the swine H3N2 is due to other factors.  
Interestingly, the swine H3N2 A/swine/Tx98/4199-2/98 used in this experiment possesses 
glutamic acid, phenylalanine and methionine at position 186, 103, 106 of its NS1 protein, 
respectively, which have been shown to be critical for the viral NS1 binding to the host factor 
CPSF and thus inhibiting the host mRNA processing (33). The inhibition of host mRNA 
processing will result in decreased expression of antiviral proteins and therefore allowing viral 
replication even in interferon treated cells. To control swine H3N2 influenza virus replication to 
a desired low level, high dosage and repeated (14) interferon pretreatment might be necessary in 
order to override its NS1 interferon antagonistic ability.  
As previously indicated, the in vivo experiment indicating administering interferon alpha 
to prevent influenza A viruses infection has shown promise in ferrets (5). Orally administrated 
chicken interferon-alpha has also been shown to inhibit avian H9N2 influenza virus replication 
in chickens (51). In humans, intranasal interferon was used successfully for prevention and 
treatment of influenza infection successfully in Moscow (3); and long term therapy with high 
dose of IFN alpha in conjunction with other drugs is being used to treat hepatitis B and C in 
humans (14) . However, the side effects of applying high doses of IFN limit its use in the 
treatment of influenza in humans. Studies have also shown that combating influenza is possible 
by using low dosage of interferon in vivo without adverse effects (3, 25). In summary, both this 
study and earlier research have demonstrated that using interferon could become a promising 
alternative for the treatment of influenza infections. 
 
In conclusion, this research has demonstrated the efficient antiviral effect of Alferon N 
(human interferon alpha) pretreatment of cells for different subtypes of influenza viruses has the 
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potential to cause future pandemics. Significantly reduced virus replication was observed with 
the treatment of Alferon N in a dose dependent manner; and low doses of interferon pretreatment 
were sufficient to cause significant inhibition. In general, by pretreating the cells for a longer 
time or by repetitive treatment, better inhibition was seen even with low treatment doses of 
treatment.  These results increase understanding about the replication of various influenza A 
viruses subtypes, as well as demonstrate the efficacy of using interferon to inhibit the replication 
of viruses in cell cultures. Furthermore, the data support the idea that interferon can be used as a 
potential antiviral drug to prevent a host from being infected by novel and lethal influenza 
viruses, especially when those viruses are drug resistant strains. This research has demonstrated 
the effect of exogenous IFN-α treatment on the replication of different influenza A viruses in 
vitro and provides a foundation for future in vivo studies on using exogenous IFN-α treatment as 
an alternative approach to combat influenza A virus infection. 
.  
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